⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2369051 | 1.00 | — | — | |
| SCHEMBL473550 | 1.00 | — | — | |
| Hydrogen Peroxide SCHEMBL28037399 | 0.97 | TSHR (0.35) | — | |
| SCHEMBL10876165 | 0.92 | TSHR (0.32) | — | |
| SCHEMBL6132259 | 0.92 | TSHR (0.32) | — | |
| SCHEMBL14720917 | 0.89 | TSHR (0.43) | — | |
| SCHEMBL21420110 | 0.83 | — | — | |
| SCHEMBL9393516 | 0.83 | EPHX2 (0.33) | — | |
| SCHEMBL4456910 | 0.83 | EPHX2 (0.33) | — | |
| SCHEMBL29700 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| EP-4422750-A1 | LRRK2 INHIBITORS | H. Lundbeck A/S (DK) | 2024-09-04 | — | — | EP | disclosed |
| CN-118251397-A | LRRK2 inhibitors | H.隆德贝克有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11993612-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2024-05-28 | — | — | US | disclosed |
| US-20230416272-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-12-28 | — | — | US | disclosed |
| US-11780851-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-11780851-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-11780851-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| WO-2023073013-A9 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-08-17 | — | — | WO | disclosed |
| WO-2011104338-A1 | HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011104338-A1 | HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
| US-20110201608-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-18 | — | — | US | disclosed |
| WO-2010130423-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-0219257-B1 | Esters of dihydrolysergic acid | LILLY CO ELI (US) | 1994-03-09 | — | — | EP | disclosed |
| US-4968802-A | ESTERIFICATION WITH ALKOXYCYCLOALKYL SULFONATE | ELI LILLY AND COMPANY (US) | 1990-11-06 | — | — | US | disclosed |
| US-4914100-A | TREATING THROMBOSIS | ELI LILLY AND COMPANY (US) | 1990-04-03 | — | — | US | disclosed |
| US-4847261-A | ANALGESICS, HYPOTENSIVES | ELI LILLY AND COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| US-4714704-A | Alkoxy cycloalkanol esters of dihydrolysergic acid useful as 5HT receptor antagonists | ELI LILLY AND COMPANY (US) | 1987-12-22 | — | — | US | disclosed |
| EP-0219257-A2 | Esters of dihydrolysergic acid | ELI LILLY AND COMPANY (US) | 1987-04-22 | — | — | EP | disclosed |